億勝生物(01061.HK)注射液HLX04-O研究結果展現初步療效
億勝生物科技(01061.HK)公布,近日,用以治療濕性AMD之重組抗血管內皮生長因子人源化單克隆抗體眼用注射液HLX04-O的1/2期臨床研究結果顯示其安全性及耐受性良好,並展現出初步療效。
HLX04-O是在復宏漢霖(02696.HK)自主研發的漢貝泰的基礎上,開發的新眼科製劑產品。2020年10月,復宏漢霖將漢貝泰於全球範圍眼科治療用途和/或療法的獨家權利許可給億勝,並約定共同開發相關產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.